Risk of Preeclampsia in HIV-Positive Pregnant Women Receiving HAART: A Matched Cohort Study

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 2, 2012, Pages 136-141

  Boyajian, Talar ^a,b   Shah, Prakesh S ^b,c   Murphy, Kellie E ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antiretroviral therapy; Highly active; HIV; Infant; Low birth weight; Preeclampsia; Pregnancy

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMALL FOR DATE INFANT; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; RISK FACTOR; STATISTICAL MODEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; LOGISTIC MODELS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84861813072     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35156-8     Document Type: Article

References (40)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic 2010, Available at, Accessed June 1, 2011. http://www.unaids.org/documents/20101123_GlobalReport_em.pdf.
2. Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance report to December 31, 2008. 2009:1-93. Available at: . Accessed March 10, 2010. http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/2008/dec/index-eng.php.
3. Connor E.M., Sperling R.S., Gelber R., Kiselev P., Scott G., O'Sullivan M.J., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
4. Cooper E.R., Charurat M., Mofenson L., Hanson I.C., Pitt J., Diaz C., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002, 29:484-494.
5. Rachlis A.R., Zarowny D.P. Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. CMAJ 1998, 158:496-505.
6. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:458-465.
7. Wimalasundera R.C., Larbalestier N., Smith J.H., de Ruiter A., McG Thom S.A., Hughes A.D., et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002, 360(9340):1152-1154.
8. Stratton P., Tuomala R.E., Abboud R., Rodriguez E., Rich K., Pitt J., et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:179-186.
9. European Collaborative Study. Pregnancy-related changes in the longer- term management of HIV-infected women in Europe. Eur J Obstet Gynecol Reprod Biol 2003, 111:3-8.
10. Suy A., Martinez E., Coll O., Lonca M., Palacio M., de Lazzari E., et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006, 20:59-66.
11. Mattar R., Amed A.M., Lindsey P.C., Sass N., Daher S. Preeclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol 2004, 117:240-241.
12. Boer K., Nellen J., Patel D., Timmermans S., Tempelman C., Wibaut M., et al. The AmRo Study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 2007, 114:148-155.
13. Kourtis A.P., Bansil P., McPheeters M., Meikle S.F., Posner S.F., Jamieson D.J. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994-2003. AIDS 2006, 20:1823-1831.
14. Haeri S., Shauer M., Dale M., Leslie J., Baker A.M., Saddlemire S., et al. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. Am J Obstet Gynecol 2009, 201:315-320.
15. European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000, 14:2913-2920.
16. Thorne C., Patel D., Newell M.L. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004, 18:2337-2339.
17. Townsend C.L., Cortina-Borja M., Peckham C.S., Tookey P.A. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007, 21:1019-1026.
18. Martin F., Taylor G.P. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single-center cohort study. J Infect Dis 2007, 196:558-561.
19. Grosch-Woerner I., Puch K., Maier R.F., Niehues T., Notheis G., Patel D., et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008, 9:6-13.
20. Tuomala R.E., Watts D.H., Li D., Vajaranant M., Pitt J., Hammill H., et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005, 38:449-473.
21. Szyld E.G., Warley E.M., Freimanis L., Gonin R., Cahn P.E., Calvet G.A., et al. Maternal antiretroviral drugs during pregnancy and infant low birthweight and preterm birth. AIDS 2006, 20:2345-2353.
22. Patel K., Shapiro D.E., Brogly S.B., Livingston E.G., Stek A.M., Bardeguez A.D., et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010, 201:1035-1044.
23. Schulte J., Dominguez K., Sukalac T., Bohannon B., Fowler M.G. Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007, 119:900-906.
24. Briand N., Mandelbrot L., Le Chenadec J., Tubiana R., Teglas J.P., Faye A., et al. ANRS French Perinatal Cohort. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009, 23:1235-1243.
25. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia. No 33, January, 2002. Obstet Gynecol 2002;99:159-67.
26. Brown M.A., Lindheimer M.D., de Swiet M., Van Assche A., Moutquin J.M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001, 20:9-14.
27. Kramer M., Platt R., Wen S., Joseph K., Allen A., Abrahamowicz M., et al. Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001, 108:35.
28. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: a systematic review of controlled studies. BMJ 2005, 330:565-567.
29. Milne F., Redman C., Walker J., Baker P., Bradley J., Cooper C., et al. The Pre-Eclampsia Community Guideline (Precog): how to screen for and detect onset of preeclampsia in the community. BMJ 2005, 330:576-580.
30. Caughey A.B., Stotland N.E., Washington A.E., Escobar G.J. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol 2005, 106:156-161.
31. Dekker G., Robillard P.Y. Pre-eclampsia: is the immune maladaptation hypothesis still standing? An epidemiological update. J Reprod Immunol 2007, 76:8-16.
32. Luo Z.C., An N., Xu H.R., Larante A., Audibert F., Fraser W.D. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol 2007, 21:36-45. (Suppl 1).
33. Firnhaber C., Smeaton L., Saukila N., Flanigan T., Gangakhedkar R., Kumwenda J., et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis 2010, 14:1088-1092.
34. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006, 44(1):132-139. Suppl.
35. Ouyang D.W., Shapiro D.E., Lu M., Brogly S.B., French A.L., Leighty R.M., et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 2009, 23:2425-2430.
36. Buka S.L. Disparities in health status and substance use: ethnicity and socioeconomic factors. Public Health Rep 2002, 117(1):118-125. Suppl.
37. Public Health Agency of Canada. Canadian Perinatal Health Report 2008, Available at, Accessed April 9, 2011. http://www.publichealth.gc.ca/cphr.
38. MacDorman M.F. Race and ethnic disparities in fetal mortality, preterm birth, and infant mortality in the United States: an overview. Semin Perinatol 2011, 35:200.
39. Anachebe N.F. Racial and ethnic disparities in infant and maternal mortality. Ethn Dis 2006, 16:71-76. Spring (2 Suppl 3).
40. Bryant A.S., Worjoloh A., Caughey A.B., Washington A.E. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. Am J Obstet Gynecol 2010, 202:335-343.